BioStem Technologies lands $2.5M from first institutional investor on path to Nasdaq
What's the deal? BioStem Technologies, a regenerative medicine company trading on the OTC market, has secured $2.5 million through a private placement with its first institutional investor. The Florida-based firm is selling 746,269 shares of common stock at $3.35 per share.
The company said it will use proceeds for working capital and general corporate purposes. BioStem specialises in developing, manufacturing, and commercialising perinatal tissue allograft products.
Why now? The deal comes as BioStem pursues a potential uplisting to Nasdaq, a move that would give it access to a broader investor base and greater liquidity. Chairman and chief executive officer Jason Matuszewski said the placement, combined with a previously announced debt retirement, strengthens the company's balance sheet.
"We expect the progress we are making toward the Nasdaq uplist and our improved capital position will provide increased flexibility to address our long-term capital needs in support of our growth plans," Matuszewski said.
What could go wrong? The issuance of over 746,000 new shares dilutes existing shareholders. More concerning, the securities purchase agreement includes anti-dilution provisions that could force BioStem to issue additional shares or pre-funded warrants if it conducts certain future offerings — potentially compounding that dilution.
Closing, expected on or about May 22, 2026, remains subject to customary conditions. BioStem must also file a resale registration statement with the SEC, adding regulatory steps to the process.
The signal: BioStem's classification as a "late growth" company on Dealroom underscores the gap between its operational maturity and its capital markets standing — still trading on the OTC market with a $2.5 million raise. Securing a first institutional backer is table stakes for a credible Nasdaq application, and the modest round size suggests BioStem is prioritising balance sheet optics over a larger, more dilutive raise to clear listing requirements.
Read more: stocktitan.net
